<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01329458</url>
  </required_header>
  <id_info>
    <org_study_id>HepFocUS</org_study_id>
    <nct_id>NCT01329458</nct_id>
  </id_info>
  <brief_title>Contrast Enhanced Ultrasound For The Evaluation Of Focal Liver Lesions</brief_title>
  <acronym>HepFocUS</acronym>
  <official_title>Contrast Enhanced Ultrasound for the Evaluation of Focal Liver Lesions - a Multi-center Study on the Usefulness in the Clinical Practice</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Societatea Romana de Ultrasonografie in Medicina si Biologie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centrul de Cercetare in Gastroenterologie si Hepatologie, Craiova</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Clinica de Gastroenterologie si Hepatologie, UMF Timisoara</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institutul Regional de Gastroenterologie &amp; Hepatologie Prof. dr. Octavian Fodor</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institutul Clinic Fundeni, Bucuresti</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Clinica de Gastroenterologie Constanta</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Societatea Romana de Ultrasonografie in Medicina si Biologie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to assess the value of contrast enhanced ultrasound in the evaluation
      of de novo focal liver lesions in clinical practice, in a prospective multi-center design.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Focal liver lesions (FLL) are quite frequently discovered in daily practice at routine
      ultrasound and sometimes require the use of extensive investigations for a correct diagnosis,
      thus increasing the costs and duration of diagnosis. On the other hand, due to screening
      strategies for patients with liver cirrhosis, FLL are discovered very early in these
      patients, and they must be evaluated in order to establish a therapeutic strategy (including
      transplantation, surgical resection or percutaneous echoguided procedures).

      Contrast enhanced ultrasound (CEUS) using second generation contrast agents is a relatively
      new imaging modality that allows the characterization of FLL and allows a positive diagnosis
      based on the vascular pattern of the lesion. The advantages of this method are the low cost
      as compared with other imaging modalities and the fact that it can be performed immediately
      after standard abdominal ultrasound, so approximately 5 minutes after CEUS (the total
      duration of this investigation) a confident diagnosis can be obtained.

      The place of CEUS in the diagnostic algorithm of FLL is not very well established. The
      European Federation of Societies for Ultrasound in Medicine and Biology (EFSUMB) issued the
      first Guidelines regarding the use of CEUS in 2004, revised in 2008, in which the main
      indications of this method are presented.

      The purpose of this study is to establish the value of CEUS in the evaluation of de novo FLL
      in clinical practice.

      The study will include patients discovered with de novo FLL at standard ultrasound in which
      the ultrasound study is not conclusive for the positive diagnosis (the patients with simple
      cysts or known FLL under CEUS follow up will be excluded form the study). The standard
      ultrasound will be followed by the contrast study using SonoVueÂ® (Bracco, Italy) as contrast
      agent. The amount of contrast agent will be documented in every patient (it depends on the
      ultrasound machine used and the suspected diagnosis). The examination will be performed using
      the dedicated contrast software of each ultrasound machine used in the study. The
      investigators shall also document in every patient: the indication for CEUS study, a short
      history including the presence of chronic hepatopathies or malignancies, the ultrasound
      machine used and the operator. Each examination will last about 5 min after bolus injection
      and will be documented by 4 video files no longer than 30 seconds each, containing: The
      standard study, the arterial phase, the portal phase and the late phase. Additional loops can
      be stored whenever it is considered necessary.

      A CEUS diagnosis will be established based on the contrast study. This will be compared with
      the final diagnosis which will be established based on all available imaging and clinical
      data: computer tomography, MRI, biopsy, follow up information. A CEUS examination will be
      considered conclusive if, following contrast, the FLL had a typical enhancement pattern
      according to the EFSUMB guidelines, and inconclusive if the enhancement pattern of the
      lesions was not in concordance with this guide.

      The stored loops will be also revised by different operators. The study design is
      prospective, multi-center and will be approved by the ethical review board.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2010</start_date>
  <completion_date type="Anticipated">December 2011</completion_date>
  <primary_completion_date type="Anticipated">December 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>evaluation of contrast enhanced ultrasound in the assessment of de novo focal liver lesions</measure>
    <time_frame>12 months evaluation</time_frame>
    <description>A CEUS examination will be considered conclusive if, following contrast, the FLL had a typical enhancement pattern according to the EFSUMB guidelines, and inconclusive if the enhancement pattern of the lesions was not in concordance with this guide.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>Focal Nodular Hyperplasia of Liver</condition>
  <condition>Toxic Liver Disease With Focal Nodular Hyperplasia</condition>
  <condition>Liver Metastases</condition>
  <arm_group>
    <arm_group_label>Focal liver lesions</arm_group_label>
    <description>Focal liver lesions: patients discovered with new, uncharacteristic focal liver lesions at standard ultrasound</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        The patients included in the study will be patients discovered with FLL at standard
        ultrasound. The focal lesions will be characterized by CEUS and the diagnosis established
        will be compared with the final diagnosis of the patient.

        The final diagnosis will be established based on all available imaging and clinical data:
        computer tomography, MRI, biopsy, follow up information.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients diagnosed with de novo FLL at standard ultrasound

          -  age &gt; 18 years, male and female gender

          -  informed consent for the contrast enhanced study

        Exclusion Criteria:

          -  patients with contraindication for contrast enhanced study: subjects with acute
             cardiac infarction, with class III/IV cardiac insufficiency, with rhythm disorders and
             pregnant women

          -  Patients diagnosed with simple cysts at standard ultrasound (biliary of hydatid)

          -  Patients with known FLL, for example after percutaneous treatment, in which the
             contrast study is used for the follow up of the patient.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mihai A Socaciu, MD, PhD student</last_name>
    <phone>0040745587847</phone>
    <email>socacium@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institutul Clinic Fundeni</name>
      <address>
        <city>Bucuresti</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institutul Regional de Gastroenterologie-Hepatologie &quot;Octavian Fodor&quot;,</name>
      <address>
        <city>Cluj-Napoca</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinica de Gastroenterologie Constanta</name>
      <address>
        <city>Constanta</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centrul de Cercetare in Gastroenterologie si Hepatologie</name>
      <address>
        <city>Craiova</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinica de Gastroenterologie si Hepatologie</name>
      <address>
        <city>Timisoara</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Romania</country>
  </location_countries>
  <link>
    <url>http://study.umfcv.ro</url>
  </link>
  <reference>
    <citation>Albrecht T, Blomley M, Bolondi L, Claudon M, Correas JM, Cosgrove D, Greiner L, JÃ¤ger K, Jong ND, Leen E, Lencioni R, Lindsell D, Martegani A, Solbiati L, Thorelius L, Tranquart F, Weskott HP, Whittingham T; EFSUMB Study Group. Guidelines for the use of contrast agents in ultrasound. January 2004. Ultraschall Med. 2004 Aug;25(4):249-56.</citation>
    <PMID>15300497</PMID>
  </reference>
  <reference>
    <citation>Claudon M, Cosgrove D, Albrecht T, Bolondi L, Bosio M, Calliada F, Correas JM, Darge K, Dietrich C, D'Onofrio M, Evans DH, Filice C, Greiner L, JÃ¤ger K, Jong Nd, Leen E, Lencioni R, Lindsell D, Martegani A, Meairs S, NolsÃ¸e C, Piscaglia F, Ricci P, Seidel G, Skjoldbye B, Solbiati L, Thorelius L, Tranquart F, Weskott HP, Whittingham T. Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) - update 2008. Ultraschall Med. 2008 Feb;29(1):28-44. doi: 10.1055/s-2007-963785.</citation>
    <PMID>18270887</PMID>
  </reference>
  <reference>
    <citation>Strobel D, Seitz K, Blank W, Schuler A, Dietrich C, von Herbay A, Friedrich-Rust M, Kunze G, Becker D, Will U, Kratzer W, Albert FW, Pachmann C, Dirks K, Strunk H, Greis C, Bernatik T. Contrast-enhanced ultrasound for the characterization of focal liver lesions--diagnostic accuracy in clinical practice (DEGUM multicenter trial). Ultraschall Med. 2008 Oct;29(5):499-505. doi: 10.1055/s-2008-1027806.</citation>
    <PMID>19241506</PMID>
  </reference>
  <reference>
    <citation>Tranquart F, Correas JM, Ladam Marcus V, Manzoni P, Vilgrain V, Aube C, Elmaleh A, Chami L, Claudon M, Cuilleron M, Diris B, Garibaldi F, Lucidarme O, Marion D, Beziat C, Rode A, Tasu JP, Trillaud H, Bleuzen A, Le Gouge A, Giraudeau B, Rusch E. [Real-time contrast-enhanced ultrasound in the evaluation of focal liver lesions: diagnostic efficacy and economical issues from a French multicentric study]. J Radiol. 2009 Jan;90(1 Pt 2):109-22. French.</citation>
    <PMID>19212279</PMID>
  </reference>
  <reference>
    <citation>Braun B. Focal liver processes: &quot;better is the enemy of good&quot;: CEUS in the fast lane. Ultraschall Med. 2009 Aug;30(4):329-32. doi: 10.1055/s-0028-1109693. Epub 2009 Aug 17. English, German.</citation>
    <PMID>19688667</PMID>
  </reference>
  <reference>
    <citation>Wilson SR, Greenbaum LD, Goldberg BB. Contrast-enhanced ultrasound: what is the evidence and what are the obstacles? AJR Am J Roentgenol. 2009 Jul;193(1):55-60. doi: 10.2214/AJR.09.2553. Review.</citation>
    <PMID>19542395</PMID>
  </reference>
  <reference>
    <citation>Trillaud H, Bruel JM, Valette PJ, Vilgrain V, Schmutz G, Oyen R, Jakubowski W, Danes J, Valek V, Greis C. Characterization of focal liver lesions with SonoVue-enhanced sonography: international multicenter-study in comparison to CT and MRI. World J Gastroenterol. 2009 Aug 14;15(30):3748-56.</citation>
    <PMID>19673015</PMID>
  </reference>
  <reference>
    <citation>Quaia E, Calliada F, Bertolotto M, Rossi S, Garioni L, Rosa L, Pozzi-Mucelli R. Characterization of focal liver lesions with contrast-specific US modes and a sulfur hexafluoride-filled microbubble contrast agent: diagnostic performance and confidence. Radiology. 2004 Aug;232(2):420-30.</citation>
    <PMID>15286314</PMID>
  </reference>
  <reference>
    <citation>von Herbay A, Vogt C, Willers R, HÃ¤ussinger D. Real-time imaging with the sonographic contrast agent SonoVue: differentiation between benign and malignant hepatic lesions. J Ultrasound Med. 2004 Dec;23(12):1557-68.</citation>
    <PMID>15557299</PMID>
  </reference>
  <verification_date>April 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 2, 2011</study_first_submitted>
  <study_first_submitted_qc>April 5, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2011</study_first_posted>
  <last_update_submitted>April 5, 2011</last_update_submitted>
  <last_update_submitted_qc>April 5, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 6, 2011</last_update_posted>
  <responsible_party>
    <name_title>Socaciu Mihai</name_title>
    <organization>Societatea Romana de Ultrasonogragrafie in Medicina si Biologie</organization>
  </responsible_party>
  <keyword>FLL</keyword>
  <keyword>CEUS</keyword>
  <keyword>SonoVue</keyword>
  <keyword>HCC</keyword>
  <keyword>Liver metastases</keyword>
  <keyword>Hemangiomas</keyword>
  <keyword>FNH</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
    <mesh_term>Focal Nodular Hyperplasia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

